Jupiter Neurosciences, Inc.
JUNS
Positions held
Your positionsJUNS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $3.65M | Enterprise value | $2.36M | Trailing P/E | — | Forward P/E | 46.17 |
| PEG | — | Price / book | -5.03 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -113.1% |
| Profit margin | 0.0% | ROE | -18.9% | ROA | -1.6% | Debt / equity | — |
| Current ratio | 0.66 | Free cash flow | -$3.26M | Analyst recommendation | none | Mean target | — |
| 52w high | $135.75 | 52w low | $2.25 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -11313.4% | -10524.3% | -12886.7% | — | — | — |
| Net income | -$2.3M | -$2.1M | -$2.6M | -$2.3M | -$2.3M | — |
| Gross margin | 86.9% | 76.6% | — | — | — | — |
| Gross profit | $0.0M | $0.0M | — | — | $0.0M | $0.0M |
| Operating income | -$2.7M | -$2.0M | -$2.8M | -$2.3M | -$2.3M | — |
- Revenue +30% vs prior quarter ($0.0M vs $0.0M).
- Gross margin 86.9% (was 76.6% prior quarter).
- Operating margin compressed to -11313.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.2M | — |
| Op margin | -40873.2% | — | — | -1471.4% | — |
| Net income | -$8.6M | -$2.4M | -$4.8M | -$5.0M | — |
| Gross margin | 80.6% | — | — | — | — |
| Gross profit | $0.0M | — | — | — | — |
| Operating income | -$8.9M | -$3.1M | -$3.9M | -$3.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Sector Update: Healthcare Stocks Mixed Late Afternoon
2026-10-06 · Sector Update: Healthcare Stocks Mixed Tuesday Afternoon
2026-10-06 · Jupiter Neurosciences Explores Strategic Options
2026-08-31 · Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-08-25 · Top Premarket Decliners
2026-08-21 · Sector Update: Healthcare Stocks Advance Late Afternoon
2026-08-21 · Jupiter Neurosciences Prices $2.0 Million Direct Offering
2026-08-21 · Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
2026-08-19 · Real Parkinson’s Disease Hope from Jupiter Neurosciences
2026-08-05 · Jupiter Neurosciences, Inc. Announces Reverse Stock Split
2026-07-22 · Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
Price (daily)
Full chart · RSI · MACD · patterns